Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, topical acyclovir significantly delayed hair growth initiation and completion in mice and reduced hair follicle size, suggesting potential inhibitory effects on hair growth.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

In this study, applying a biodegradable microneedle patch after topical steroid application significantly increased steroid penetration and improved treatment outcomes in patients with prurigo nodularis compared to the control.

This study developed a stable, cosmetically appealing formulation for the topical delivery of the peptide FOL-005, enhancing skin permeation and maintaining stability by keeping the peptide solid and in a water-free environment with particle sizes under 10 µm.

In this case report, a 9-year-old girl using topical minoxidil for alopecia experienced a 6-second asystole with syncope, suggesting careful cardiac monitoring may be needed for minoxidil users.

This case study reports that reducing scalp massage following minoxidil application and using mesenchymal stem cell exosomes led to significant improvement in hair condition for a patient with trichorrhexis nodosa.

This study found that a new propylene glycol-free 5% minoxidil lotion demonstrated good clinical efficacy and very good cosmetic acceptability and tolerability after six months of use in patients with androgenetic alopecia, showing results comparable to traditional formulations containing propylene glycol.

In this study, researchers examined a new propylene glycol-free 5% minoxidil lotion for 6 months among individuals with androgenic alopecia and found it demonstrated good clinical efficacy, with 74% showing a positive response, and very high cosmetic acceptability and tolerability, comparable to traditional formulations.

This study described the development and evaluation of a finasteride nanogel for treating androgenetic alopecia, reporting higher cumulative drug release and enhanced spreadability compared to a plain gel, suggesting potential as a treatment option.

In this study, 15d-PGJ2 administered in a topical cream inhibited oxidative and inflammatory skin changes caused by UVB radiation in hairless mice, suggesting it as a promising treatment approach.

This study suggests that the novel "After Minoxidil" spray improved styling ease and reduced greasiness in patients using topical minoxidil, which may enhance compliance and treatment efficacy.

This study observed that combining nonablative fractional laser treatment with topical minoxidil led to hair regrowth in Chinese alopecia areata patients, noting complete regrowth in some patients and no relapse in the majority at a one-year follow-up, without reported side effects.

This case report describes a non-arteritic anterior ischemic optic neuropathy that resolved after discontinuing topical 5% minoxidil treatment.

This source reports that topical minoxidil effectively treats hair loss in androgenetic alopecia, varying efficacy by ethnic groups, and when combined with other therapies, shows increased effectiveness for conditions like alopecia areata and congenital hair disorders.

This study found that applying 5% topical minoxidil gel on treatment-resistant vitiligo patches may promote early repigmentation, showing significant improvement at one month compared to a placebo, though later differences were not statistically significant.

This source describes vitiligo as a chronic condition marked by the loss of skin pigmentation and discusses leukotrichia, a feature affecting 10% to 60% of cases, which arises from melanocyte loss in hair follicles and appears as well-defined white patches on the skin.

This review discusses the progress in research on topical formulations for treating alopecia, highlighting potential advantages of advanced formulation technologies but reporting no new clinical results.

This study found that finasteride- and dutasteride-loaded iron oxide nanoparticles improved drug penetration in the skin, suggesting they may be promising for topical alopecia therapies.

This paper introduces a novel topical booster aimed at enhancing follicular sulfotransferase activity to potentially improve minoxidil response in patients with androgenetic alopecia but reports no new clinical results.

This research highlights the potential of emulgel as an advanced topical drug delivery system, offering improved efficacy for hydrophobic medications in treating dermatological conditions and a range of ailments with its dual release control mechanism of gel and emulsion.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

This study found that the optimized AR antagonist compound 39 showed potent hair growth activity with improved safety in mice, suggesting potential for better topical treatments for androgenetic alopecia.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.

This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.

In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.